CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

Oncology Media Relations oncology_media_relations@its.jnj.com   Investor contact: Jessica Margevich investor-relations@its.jnj.com ...

Today, many men must choose between life-altering prostate removal or careful long-term monitoring. The EU-funded ROBIOSPY Project offers an intermediate option: precise needle-based diagnostics and ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

SIOUX CITY (KTIV) - Prostate cancer is one of the most common cancers in men. With the thousands of cases reported every year in the United States, treatment is crucial. November is Men’s Health ...

During last night's game presented by Emory Healthcare, the Atlanta Hawks Foundation, together with the Ressler Gertz Family Foundation, announced a $150,000 donation to the Prostate Cancer Foundation ...